| Date | Title | |
| December 13, 2006 | Pozen Expects to Submit Revised Response to Trexima(TM) (Sumatriptan/Naproxen Sodium) Approvable Letter by Year End |  |
| December 07, 2006 | POZEN To Present at the 2006 RBC Capital Markets Healthcare Conference | |
| November 30, 2006 | POZEN to Present at the BMO 6th Annual Investor Conference - Focus on Healthcare | |
| November 21, 2006 | POZEN to Present at the Lazard Capital Markets Third Annual Life Sciences Conference | |
| November 09, 2006 | POZEN Submits Full Response to FDA Approvable Letter For Trexima™ | |
| November 01, 2006 | POZEN to Present at the Cowen & Company 7th Annual Global Health Care Conference | |
| October 31, 2006 | POZEN Reports Third Quarter 2006 Results | |
| October 23, 2006 | POZEN To Ring NASDAQ Closing Bell | |
| October 17, 2006 | POZEN Announces October 31 Webcast of Third Quarter 2006 Results | |
| September 21, 2006 | POZEN Announces Receipt of $40 Million Upfront Payment from AstraZeneca; Company Provides Revised 2006 Guidance | |
| September 20, 2006 | New Analysis Shows Patients Who Treat Their Migraine Pain Early With Trexima™ (Sumatriptan Succinate/Naproxen Sodium) Have Higher Sustained Pain-Free Rates Than Those Who Treat Late | |
| September 20, 2006 | New Data Show Consistent Efficacy and Tolerability of Trexima™ (Sumatriptan Succinate/Naproxen Sodium) Across Multiple Migraine Attacks | |
| September 20, 2006 | New Data Show Peak Concentration of Sumatriptan Occurred Earlier With Trexima™ (Sumatriptan Succinate/Naproxen Sodium) Compared to Imitrex® (Sumatriptan Succinate) | |
| September 13, 2006 | POZEN To Present at the UBS 2006 Global Life Sciences Conference | |
| September 05, 2006 | POZEN To Present at the Bear Stearns 19th Annual Healthcare Conference | |
| August 03, 2006 | Pozen Reports Second Quarter 2006 Results | |
| August 02, 2006 | POZEN and AstraZeneca Announce Global Collaboration to Co-Develop and Commercialize Fixed Dose Combinations of Naproxen and Esomeprazole for the Treatment of Pain | |
| July 31, 2006 | POZEN to Submit Full Response to Trexima™ Approvable Letter During the Fourth Quarter | |
| July 25, 2006 | POZEN Announces August 3 Webcast of Second Quarter 2006 Results | |
| June 26, 2006 | New Data Show Investigational Migraine Therapy Demonstrates Effective Treatment of Migraine-Associated Neck and Sinus Pain | |
| June 26, 2006 | New Data Demonstrate Sustained Efficacy of Single Tablet Combination Migraine Therapy Compared to Monotherapy | |
| June 09, 2006 | POZEN Inc. and Glaxosmithkline Report Receipt of Approvable Letter for Investigational Migraine Treatment | |
| April 27, 2006 | POZEN Reports First Quarter 2006 Results | |
| April 20, 2006 | POZEN Announces Completion of Special Protocol Assessment for PN 200; New Arthritis Product Phase III Trials to Begin on Schedule | |
| April 13, 2006 | POZEN Announces April 27 Webcast of First Quarter 2006 Results | |
| April 05, 2006 | New Data Presented on Satisfaction, Productivity and Long-Term Safety of a Single Tablet Containing Sumatriptan Formulated With RT Technology(TM) and Naproxen Sodium | |
| April 05, 2006 | New Pivotal Trial Data Demonstrated Superior Clinical Benefits of Single Tablet Containing Sumatriptan Formulated With RT Technology(TM) and Naproxen Sodium | |
| April 04, 2006 | POZEN to Present at the SunTrust Robinson Humphrey 35th Annual Institutional Conference | |
| March 16, 2006 | POZEN Announces Changes to Its Board of Directors; The Company Appoints Donald H. Namm and James J. Mauzey and Accepts the Resignations of Ted G. Wood and James R. Butler | |
| March 02, 2006 | POZEN to Present at Cowen & Co. 26th Annual Health Care Conference | |
| March 01, 2006 | POZEN Reports Fourth Quarter and Year End 2005 Results; $20 Million Milestone Payment from GSK Contributes to Profitability; Lornoxicam Phase II Studies Initiated in Acute Pain And Migraine | |
| February 22, 2006 | POZEN Announces Change of Date for Webcast of Fourth Quarter and Year End Results | |
| February 16, 2006 | POZEN Announces March 2 Webcast of Fourth Quarter and Year End Results | |
| February 10, 2006 | Company Profile for POZEN Inc. | |
| February 09, 2006 | POZEN to Present on Panel at the BIO CEO & Investor Conference | |
